Ahmed Sobhy Abdelrahim Abdallah Darwish | Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Ahmed Sobhy Abdelrahim Abdallah Darwish | Cell Biology | Research Excellence Award

Zagazig University & Egyptian International Pharmaceutical Industries Company, EIPICO | Egypt

Ahmed Sobhy Abdelrahim Abdallah Darwish is a highly accomplished analytical chemist with extensive expertise in analytical methodologies and chemical research. His academic journey demonstrates a consistent commitment to scientific rigor, progressing from a strong foundation in chemistry and physics to advanced studies in analytical chemistry. He has completed a diploma in analytical chemistry with distinction, a pre-master qualification with outstanding performance, and a master’s degree in analytical chemistry. Currently pursuing a Ph.D. in the same field, his research is centered on the development, optimization, and validation of analytical techniques for pharmaceutical and industrial applications. His work emphasizes precision, reliability, and innovation in chemical analysis, including method development for complex matrices, quality control protocols, and instrumental analysis techniques. His contributions aim to enhance the accuracy and efficiency of laboratory workflows, ensuring robust and reproducible results in pharmaceutical and chemical research. Additionally, he demonstrates proficiency in data interpretation, statistical analysis, and experimental design, contributing to high-quality scientific outcomes. His ongoing research reflects a commitment to advancing analytical chemistry through both theoretical insights and practical applications, positioning him as a significant contributor to the field and a strong candidate for recognition in research excellence.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications: 

Ma, J. K., Darwish, A. S., Al Ali, A., Abdelazim, A. M., Darwish, W. S., Li, X., & Huang, X. C. (2025). An ecologically sound HPLC determination of LEVOMENOL in topical therapies using a certified reference material with green properties. Results in Chemistry, 13, 102338.

Alenezi, S. S., Gouda, A. A., El Sheikh, R., Badahdah, N. A., Alzuhiri, M. E., & others. (2025). Environmental sustainability profiles assessment of HPLC stability indicating method for quantitation of piracetam and vincamine in pharmaceutical medications. Talanta Open, 11, 100407.

Darwish, A. S., Zaki, M. S. A., Salih, A. G. K. A., Ellatif, M. A., Patel, A. A., Mallick, A. K., & others. (2025). A simple eco‐friendly stability‐indicating HPLC method for determination of NETILMICIN in bulk and ophthalmic solution. Biomedical Chromatography, 39(8), e70152.

Gouda, A. A., Elsheikh, R., Eldien, A. S., & Darwish, A. S. (2025). Development and validation of stability indicating RP-HPLC method for simultaneous determination of simvastatin and fenofibrate in bulk and dosage form. Bulletin of Faculty of Science, Zagazig University, 2025(3), 134–146.

Huang, X. C., Darwish, A. S., Darwish, W. S., Chen, R. M., & Ma, J. K. (2025). Green rapid HPLC method for testing retinol and tocopherol in ophthalmic gels. Talanta Open, 100538.

Darwish, A. S., Gouda, A. A., & Eldien, A. S. (2025). Simple validated approach to quantify valsartan and sacubitril in medications using liquid chromatography. Bulletin of Faculty of Science, Zagazig University, 2025(3), 216–229.

Darwish, W. S. D., Zaki, M. S. A., Salih, A. G. K. A., & others. (2025). Developing a sensitive, ecological, and economic HPLC method for the concurrent quantification of KOLCHICINE and KHELLIN, used in bulk and sachet pharmaceuticals. Microchemical Journal, 114716.

Ma, J. K., Chen, X. Y., Zhang, N., Darwish, A. S., Gouda, A. A., El Sheikh, R., & others. (2025). A straightforward HPLC approach to testing butylated hydroxytoluene, an antioxidant, in pure and topical anti-burn gels; evaluation of greenness, blueness, and whiteness grades. Talanta Open, 100565.

Huang, X. C., Darwish, A. S., Darwish, W. S., Zaki, M. S. A., Lin, Y. T., Liang, N. L., & Ma, J. K. (2025). Ecologically conscious profiles assessments for economic, and concurrent HPLC detection of chlordiazepoxide and clidinium bromide in bulk and tablets solid dosage form. Results in Chemistry, 1, 102739.

Zhi Guo | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr Zhi Guo | Stem Cell Research | Best Researcher Award

Prof. Dr Zhi Guo | Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital | China

Dr. Zhi Guo is a distinguished expert in hematology with over 25 years of clinical and academic experience. Currently serving as Director, Academic Leader, Chief Physician, and Professor at the Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, he has been instrumental in advancing hematologic malignancy treatments in China. With extensive expertise in hematopoietic stem cell transplantation, Dr. Guo has successfully performed more than 1,300 transplant cases. He began his career at the PLA Army General Hospital, serving there for nearly two decades before transitioning to his current role. A prolific researcher, he has authored over 10 peer-reviewed publications and five books, contributing substantially to the understanding of CAR-T therapy, gut microbiota, and transplantation immunology. He is an active member of major national and international hematology associations and plays a vital role in formulating clinical consensus and guidelines in China.

publication profile:

Scopus

Strengths for the Award:

Dr. Zhi Guo exemplifies the qualities of an outstanding medical researcher and clinician. With nearly 25 years of clinical experience in hematology and over 20 years in hematopoietic stem cell transplantation, he stands out as a national leader in this field. His performance of more than 1,300 transplants, along with a strong academic footprint, including 10 SCI-indexed publications in 2024–2025, demonstrates both depth and innovation in his research. He has also contributed to national expert consensus and clinical guidelines, particularly in CAR-T therapy and intestinal microecology. Dr. Guo’s leadership roles across national academic committees and his active membership in the American Society of Hematology further highlight his international impact and collaborative influence.

Areas for Improvement:

While Dr. Guo’s achievements in clinical practice and research are significant, opportunities exist to increase global visibility by expanding his research collaborations internationally and publishing in higher-impact journals beyond regional scopes. Additionally, while five books have been authored, the addition of patents or translational innovations could enhance his profile in the realm of research commercialization and practical medical technologies.

Education :

Dr. Zhi Guo holds a strong academic background in clinical medicine and medical research. He earned his Bachelor’s degree in Medicine from Tongji Medical College in 2000. Subsequently, he pursued his postgraduate medical studies at the Third Military Medical University, completing it in 2007. His academic journey culminated with the attainment of a Doctor of Medicine (MD) degree from Wuhan University of Science and Technology. His education laid a strong foundation in hematology and clinical research methodologies. Each step in his educational path was marked by an emphasis on academic rigor and clinical competence, preparing him for a leadership role in medical science and hematologic research. His multidisciplinary background has enabled him to integrate clinical insights with advanced laboratory-based innovations, contributing to national-level guidelines and the development of cutting-edge CAR-T cell therapies and transplantation techniques.

Experience :

Dr. Zhi Guo brings nearly 25 years of clinical, academic, and leadership experience in the field of hematology. He began his professional journey at the PLA Army General Hospital, where he served from 2000 to 2018. During this period, he honed his clinical and procedural expertise in managing complex hematologic disorders. Since 2018, he has been leading the Department of Hematology at Huazhong University of Science and Technology Union Shenzhen Hospital as Director, Academic Leader, and Chief Physician. His rich experience includes more than 1,300 hematopoietic stem cell transplantations, encompassing autologous, allogeneic, and CAR-T integrated therapies. His leadership extends beyond clinical care, as he also mentors postgraduate medical students and leads multiple national and institutional research projects. Dr. Guo’s practical experience is balanced with his strategic contributions to medical consensus formulation and research-driven policy initiatives in cancer and immune-hematological disorders.

Research Focus :

Dr. Zhi Guo’s research centers on hematologic malignancies and hematopoietic stem cell transplantation, particularly the integration of cellular immunotherapy such as CAR-T cell treatments. His recent work includes pioneering anti-CD19, anti-CD7, and anti-BCMA CAR-T therapies for lymphomas and leukemias. Additionally, he has investigated the interplay between microbiota and immune modulation in transplantation, highlighting the role of gut and oral microbiomes in patient outcomes. His contributions have influenced the development of clinical guidelines for microbiota-related diagnostics and treatments in oncology. With more than 10 high-impact journal publications and ongoing projects in translational medicine, Dr. Guo’s work combines laboratory innovation with patient-centered applications. He has also authored expert consensus documents and national guidelines, helping shape China’s hematology and transplantation protocols. His commitment to interdisciplinary collaboration, clinical innovation, and translational research underscores his leading role in advancing modern hematology.

Publications Top Notes:

  1. 🧬 In vitro validation of anti-CD19 CAR-T cells with LSD1 shRNA for DLBCL – Front Immunol, 2025

  2. 🩸 Case of T-ALL treated with chemo + anti-CD7 CAR-T (retroviral vector) – Front Immunol, 2025

  3. 👶 Shaping oral/intestinal microbiota & immunity in first 1,000 days of life – Front Pediatr, 2025

  4. 💩 Fecal microbiota transplantation in acute GVHD treatment – J Cancer Res Ther, 2024

  5. 🔬 Chinese consensus on gut microecology lab standards – Exp Ther Med, 2024

  6. 🧪 2024 Chinese guidelines for intestinal microecology in cancer – J Cancer Res Ther, 2024

  7. 🧫 First MM case treated with ASCT + anti-BCMA CAR-T (retrovirus) – Heliyon, 2024

  8. 🧾 Rapid response in relapsed FL to anti-CD19 CAR-T with CMV – Int Immunopharmacol, 2024

  9. 🦷 Prognostic impact of oral microbiome in cancer survival – meta-analysis – Syst Rev, 2024

  10. 🧍‍⚕️ Expert consensus on gut microbiome & hematopoietic stem cell transplantation – Clin Transplant, 2024

Conclusion:

In conclusion, Dr. Zhi Guo is highly suitable for the Best Researcher Award. His combination of clinical excellence, academic leadership, and impactful research in hematology and stem cell transplantation positions him among the top contributors in this specialized field. With ongoing research in CAR-T cell therapies, microbiota influence on transplantation, and immuno-oncology, Dr. Guo continues to shape the future of hematologic cancer care. Recognizing his contributions with this award would be both fitting and encouraging for continued innovation in this vital area of medicine.